Back to search
FDAFDA · Food and drugs·Recall number D-1543-2020

Metformin Hydrochloride Extended-Release Tablets USP, 500 mg 1000 Tablets Rx Only Manufactured by: Beximco Pharmaceuticals, LTD. 126, Kathaldia, Tongi, Gazipur, 1711, Bangladesh NDC 76385-128-10

Published September 2, 2020 · Recall initiated: August 19, 2020

Summary

FDA records drug Class II recall D-1543-2020, published September 2, 2020 and initiated August 19, 2020. Recalling firm: BAYSHORE PHARMACEUTICALS; Status: Terminated; Reported quantity: 594 bottles; Lot: Lot #18641; Exp. 05/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email if METFORMIN HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
METFORMIN HYDROCHLORIDE
Manufacturer
BAYSHORE PHARMACEUTICALS
Distributor
nationwide
Lot
Lot #18641; Exp. 05/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metformin Hydrochloride Extended-Release Tablets USP, 500 mg 1000 Tablets Rx Only Manufactured by: Beximco Pharmaceuticals, LTD. 126, Kathaldia, Tongi, Gazipur, 1711, Bangladesh NDC 76385-128-10 recalled?

Yes. FDA published recall D-1543-2020 on September 2, 2020. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: METFORMIN HYDROCHLORIDE.